Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double Blind, Placebo Controlled, Dose-Ranging Study in Subjects With Postherpetic Neuralgia (PHN) to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Four Doses of TAK-583, Compared With Placebo

NCT00377598 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT00377598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00377598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double Blind, Placebo Controlled, Dose-Ranging Study in Subjects With Postherpetic Neuralgia (PHN) to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Four Doses of TAK-583, Compared With Placebo
Lead sponsor
Takeda
Phase
Phase 2/3
Overall status
Completed
Start date
October 31, 2006
Completion date
February 29, 2008
Enrollment
399 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

neuralgia, postherpetic